CommercialCoverageMedium impact
08.00.04b, crizanlizumab-tmca (Adakveo®)
Independence Blue Cross·Hematology, Oncology, Internal Medicine +1 more·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.04b for crizanlizumab-tmca (Adakveo®) has been updated effective July 28, 2025. This recent update involves changes to medical necessity criteria, medical coding guidelines, and general policy information for this sickle cell disease medication. The billing team must review the full policy text to identify specific coding and coverage requirement changes.
Action Required
By July 28, 2025: Billing team must access the full policy text at the provided URL to identify specific HCPCS codes (likely J-codes for this biologic injection), updated medical necessity criteria, and any prior authorization requirements for crizanlizumab-tmca claims. Update billing software, encounter forms, and staff training documentation to reflect new coding and coverage rules. Communicate changes to providers in relevant specialties. Failure to implement updates may result in claim denials for non-compliant submissions.